← ResMed
Episodes featuring ResMed
12 episodes, newest first.
- Nov 12, 2026
Why business weaknesses matter more than sector labelsStock TakeNov 12, 2026 - Oct 25, 2026
Data-centre backlash tests AI infrastructure’s growth storyEquity Mates Investing PodcastOct 25, 2026 - Sep 18, 2026
Volatility widens Australia’s value-investing gapThe Rules of InvestingSep 18, 2026 - Sep 18, 2026
Value investors find opportunity in Australia’s fallen angelsThe Rules of InvestingSep 18, 2026 - Aug 23, 2026
Moderna’s melanoma vaccine tests biotech optimismEquity Mates Investing PodcastAug 23, 2026 - Aug 12, 2026
Strong earnings meet stubborn valuation fearsEquity Mates Investing PodcastAug 12, 2026 - Aug 6, 2026
Eight stocks face defining tests this reporting seasonStock TakeAug 6, 2026 - Jul 23, 2026
An unconventional builder meets an uncertain AI boomStock TakeJul 23, 2026 - Jul 10, 2026
Employee ownership meets ADHD and Australia’s invention legacyThe Contrarians with Adam and AdirJul 10, 2026 - May 11, 2026
Cramer sees tech-bubble echoes as cybersecurity stocks seek a reboundMad Money w/ Jim CramerMay 11, 2026 - Oct 6, 2025
OpenAI’s AMD bet puts AI growth and power demand under scrutinyMad Money w/ Jim CramerOct 6, 2025 - Oct 1, 2025
Jabil bets on AI infrastructure as Cramer weighs market winnersMad Money w/ Jim CramerOct 1, 2025